Evidence map›Paper›PMID 26374428›Full record

ArticleJournal of the National Cancer Institute2015

Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms.

Jonine D Figueroa, Stella Koutros, Joanne S Colt, Manolis Kogevinas, Montserrat Garcia-Closas, Francisco X Real, Melissa C Friesen, Dalsu Baris, Patricia Stewart, Molly Schwenn and 24 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 5 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Review
  9. Integrative Analysis ofInternational journal of molecular sciences · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Risk Factors Associated with Urothelial Bladder Cancer.International journal of environmental research and public health · 2024
    Review
  14. Occupational exposure to organic solvents and risk of bladder cancer.Journal of exposure science & environmental epidemiology · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 11 institutions in 3 countries.

Jonine D FigueroaDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Stella KoutrosDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Joanne S ColtDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Manolis KogevinasDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Montserrat Garcia-ClosasDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Francisco X RealDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Melissa C FriesenDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Dalsu BarisDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Patricia StewartDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Molly SchwennDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Alison JohnsonDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Margaret R KaragasDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Karla R ArmentiDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Lee E MooreDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Alan SchnedDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Petra LenzDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Ludmila Prokunina-OlssonDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
A Rouf BandayDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Ashley PaquinDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Kris YlayaDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Joon-Yong ChungDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Stephen M HewittDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Michael L NickersonDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Adonina TardónDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Consol SerraDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Alfredo CarratoDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Reina García-ClosasDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Josep LloretaDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Núria MalatsDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Joseph F FraumeniDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Stephen J ChanockDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Nilanjan ChatterjeeDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Nathaniel RothmanDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Debra T SilvermanDivision of Cancer Epidemiology and Genetics (JDF, SK, JSC, MGC, MCF, DB, PS, LEM, LPO, ARB, AP, JFFJr, SJC, NC, NR, DTS), Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research (KY, JYC, SMH), and Cancer and Inflammation Program (MLN), National Cancer Institute, Bethesda, MD; Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh UK (JDF); CIBERESP, CIBER Epidemiologia y Salud Publica, Madrid, Spain (MK, AT, JL); Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain (MK); Municipal Institute of Medical Research (IMIM-Hospital del Mar), Barcelona, Spain (MK); Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK (MGC); Spanish National Cancer Research Centre (CNIO), Madrid, Spain (FXR, NM); Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain (FXR, CS); Maine Cancer Registry, Augusta, ME (MS); Vermont Cancer Registry, Burlington, VT (AJ); Geisel School of Medicine at Dartmouth, Hanover, NH (MRK, AS); New Hampshire Department of Health and Human Services, Concord, NH (KRA); Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD (PL); Molecular Epidemiology Group, Instituto Universitario de Oncologia, Universidad de Oviedo, Oviedo, Asturias, Spain (AT); Hospital Ramón y Cajal, Elche, Madrid, Spain (AC); Unidad de Investigación, Hospital Universitario de Canarias, La Laguna, Spain (RGC).
Institute of Cancer Research · GBCancer Genetics (United States) · USDartmouth College · USFrederick National Laboratory for Cancer Research · USHospital Universitario Ramón y Cajal · ESInstituto de Salud Carlos III · ESMunicipal Institute for Medical Research · ESNational Institutes of Health · USPompeu Fabra University · ESUniversidad de Oviedo · ESVermont Cancer Support Network · US

Funding

NONMELANOMA SKIN CANCER IN NEW HAMPSHIRER01CA057494 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1993 to 2015
$10.9M
Cancer Genetic Markers of SusceptibilityZIACP010187 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CHANOCK, STEPHEN J. · 2009 to 2025
$4.7M
Intramural NIH HHSNCI NIH HHS R01 CA057494
6 · The paper itself

Abstract

Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction we observed for rs798766 (TMEM129-TACC3-FGFR3) with specific exposure to straight metalworking fluids illustrates the value of integrating germline genetic variation, environmental exposures, and tumor marker data to provide insight into the mechanisms of bladder carcinogenesis.

Indexed as

Gene-Environment InteractionPolymorphism, Single NucleotideAdultAgedFemaleGene DeletionGenetic Predisposition to DiseaseGerm-Line MutationGlucuronosyltransferaseGlutathione TransferaseHumansMaleMetallurgyMicrotubule-Associated ProteinsMiddle AgedOccupational DiseasesFGFR3 protein, humanGlucuronosyltransferaseGlutathione TransferaseMicrotubule-Associated ProteinsReceptor, Fibroblast Growth Factor, Type 3TACC3 protein, humanTMEM129 protein, humanUbiquitin-Protein LigasesUGT1A1 Enzyme

Identifiers

PMID26374428
PMCPMC4675099
OpenAlexW1833843483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.